New York will receive about $12 million from a settlement over delays between 2006 and 2012 in allowing generic versions of the prescription drug Provigil into the marketplace.
The settlement, announced Thursday, stemmed from an agreement between the Federal Trade Commission and Cephalon in FTC v. Cephalon, 2:08-cv-2141 (E.D. Penn.). The government had alleged the drug manufacturer improperly sought to delay approvals for generic versions of Provigil so it could continue to profit from its patent-protected monopoly.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
